Healthcare stocks were slightly higher Tuesday afternoon, with the NYSE Healthcare Sector Index adding about 0.2% and shares of healthcare companies in the S&P 500 climbing 0.2% as a group.
In company news, McKesson ( MCK ) was higher Tuesday after the drug wholesaler reported year-over-year improvement in its fiscal Q4 financial results, also topping analyst estimates for the period.
MCK posted Q4 EPS of $2.55, up from a $1.48 gain during the year-ago quarter and beating analyst estimates by $0.15 per share. Revenue rose 25% over the same quarter last year to $38.1 billion, beating the Capital IQ consensus by around $2.3 million.
For the new fiscal year running through next March, MCK expects per-share earnings in a range of $10.40 to $10.80 per share, in line with analyst estimates looking for EPS of $10.62.
MCK shares were up 3.3% at $179.87 each in recent trade, climbing to a session high of $181.00 a share earlier.
In other sector news,
(-) APRI, (-1.3%) Receives FDA approval to begin Phase IIa testing of its RayVa topical cream - a combination of alprostadil and the company's proprietary permeation enhancer DDAIP.HCl - as a prospective treatment for Raynaud's phenomenon.
(-) ARNA, (-5.0%) Q1 net loss of $0.12 per share was $0.02 wider than the Capital IQ consensus. Revenue grows 186.9% over year-ago levels to $6.8 mln but still lag estimates by around $1.18 mln.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.